Advertisement

Risk of drug interactions and prescription appropriateness in elderly patients

  • Elisa Petrini
  • Gian Paolo Caviglia
  • Rinaldo Pellicano
  • Giorgio Maria Saracco
  • Mario Morino
  • Davide Giuseppe RibaldoneEmail author
Original Article

Abstract

Background

In Europe, adverse drug reactions and drug interactions are the cause of considerable morbidity and mortality. In over 75s, hospital access due to adverse drug reactions can be as high as 1 in every 3.

Aims

To assess the quality of the prescribed polytherapies in the territory, in terms of the risk of drug interactions and of prescription appropriateness, in over 75s.

Methods

Randomly selected patients, over 75s, were analysed among the patients of 3 general practitioners. Their data were analysed with the INTERCheck® software. This software provided the list of drug interactions deriving from the chronic therapies. The program also provided the Beers criteria and the STOPP criteria related to the drugs, highlighting potentially inappropriate drugs.

Results

A total of 188 patients were included in the study. A total of 216 serious or very serious drug interactions have been identified. A total of 92 patients (48.9%) were at risk of at least one serious or very serious interaction. The cut-off of the correlation between the number of drugs taken and the risk of incurring a serious or very serious interaction was found to be 5 (AUC = 0.833, sensitivity = 87%, p < 0.001). Patients on ≥ 4 drugs were at risk of prescriptive inappropriateness with a sensitivity of 84% (AUC = 0.781, p < 0.0001).

Conclusions

Focusing on patients with at least 4 drugs in therapy is the right strategy to reduce the risks associated with polypharmacy.

Keywords

Acetylsalicylic acid Benzodiazepines Escitalopram Furosemide PPI Sertraline 

Notes

Acknowledgements

The authors thank Dr. Rinaldi, Dr. Verdi and Dr. Perosino for making their databases, their patients and their work available to the study.

Compliance with ethical standards

Informed consent was obtained from all individual participants included in the study.

Conflict of interest

The authors declare that they have no conflict of interest.

Supplementary material

11845_2019_2148_MOESM1_ESM.docx (14 kb)
ESM 1 (DOCX 13 kb)
11845_2019_2148_MOESM2_ESM.docx (13 kb)
ESM 2 (DOCX 12 kb)
11845_2019_2148_MOESM3_ESM.docx (14 kb)
ESM 3 (DOCX 14 kb)
11845_2019_2148_MOESM4_ESM.docx (13 kb)
ESM 4 (DOCX 12 kb)
11845_2019_2148_MOESM5_ESM.docx (13 kb)
ESM 5 (DOCX 12 kb)
11845_2019_2148_MOESM6_ESM.docx (13 kb)
ESM 6 (DOCX 12 kb)
11845_2019_2148_MOESM7_ESM.docx (13 kb)
ESM 7 (DOCX 12 kb)
11845_2019_2148_MOESM8_ESM.docx (13 kb)
ESM 8 (DOCX 12 kb)
11845_2019_2148_MOESM9_ESM.docx (14 kb)
ESM 9 (DOCX 13 kb)
11845_2019_2148_MOESM10_ESM.docx (13 kb)
ESM 10 (DOCX 13 kb)

References

  1. 1.
    Mazzola P, Rimoldi SML, Rossi P et al (2016) Aging in Italy: the need for new welfare strategies in an old country. Gerontologist 56:383–390.  https://doi.org/10.1093/geront/gnv152 CrossRefPubMedGoogle Scholar
  2. 2.
    European Commission (2018) The 2018 Ageing Report: economic and budgetary projections for the EU member states (2016–2070).Google Scholar
  3. 3.
    Edwards IR, Aronson JK (2000) Adverse drug reactions: definitions, diagnosis, and management. Lancet 356:1255–1259.  https://doi.org/10.1016/S0140-6736(00)02799-9 CrossRefPubMedGoogle Scholar
  4. 4.
    Hazell L, Shakir SAW (2006) Under-reporting of adverse drug reactions. Drug Saf 29:385–396.  https://doi.org/10.2165/00002018-200629050-00003 CrossRefPubMedGoogle Scholar
  5. 5.
    Ribeiro-Vaz I, Santos CC, Cruz-Correia R (2016) Promoting adverse drug reaction reporting: comparison of different approaches. Rev. Saude Publica 50:14.  https://doi.org/10.1590/S1518-8787.2016050006122 CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Chan M, Nicklason F, Vial JH Adverse drug events as a cause of hospital admission in the elderly. Intern Med J 31:199–205CrossRefGoogle Scholar
  7. 7.
    Becker ML, Kallewaard M, Caspers PWJ et al (2007) Hospitalisations and emergency department visits due to drug-drug interactions: a literature review. Pharmacoepidemiol Drug Saf 16:641–651.  https://doi.org/10.1002/pds.1351 CrossRefPubMedGoogle Scholar
  8. 8.
    Laursen J, Kornholt J, Betzer C et al (2018) General practitioners’ barriers toward medication reviews in polymedicated multimorbid patients: how can a focus on the pharmacotherapy in an outpatient clinic support GPs? Heal Serv Res Manag Epidemiol 5:2333392818792169.  https://doi.org/10.1177/2333392818792169 CrossRefGoogle Scholar
  9. 9.
    By the American Geriatrics Society 2015 Beers Criteria Update Expert Panel (2015) American Geriatrics Society 2015 Updated Beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc 63:2227–2246.  https://doi.org/10.1111/jgs.13702 CrossRefGoogle Scholar
  10. 10.
    Hamilton H, Gallagher P, Ryan C et al (2011) Potentially inappropriate medications defined by STOPP criteria and the risk of adverse drug events in older hospitalized patients. Arch Intern Med 171:1013–1019.  https://doi.org/10.1001/archinternmed.2011.215 CrossRefPubMedGoogle Scholar
  11. 11.
    Antoniazzi S, Chiarelli MT, Nobili A et al (2015) The value of software that provides clinically relevant information on drug interactions. Eur J Intern Med 26:e52–e53.  https://doi.org/10.1016/j.ejim.2015.07.004 CrossRefPubMedGoogle Scholar
  12. 12.
    Mantelli S, Jungo KT, Rozsnyai Z et al (2018) How general practitioners would deprescribe in frail oldest-old with polypharmacy — the LESS study. BMC Fam Pract 19:169.  https://doi.org/10.1186/s12875-018-0856-9 CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Green JL, Hawley JN, Rask KJ (2007) Is the number of prescribing physicians an independent risk factor for adverse drug events in an elderly outpatient population? Am J Geriatr Pharmacother 5:31–39CrossRefGoogle Scholar
  14. 14.
    Nobili A, Pasina L, Tettamanti M et al (2009) Potentially severe drug interactions in elderly outpatients: results of an observational study of an administrative prescription database. J Clin Pharm Ther 34:377–386.  https://doi.org/10.1111/j.1365-2710.2009.01021.x CrossRefPubMedGoogle Scholar
  15. 15.
    Bjerrum L, Andersen M, Petersen G, Kragstrup J (2003) Exposure to potential drug interactions in primary health care. Scand J Prim Health Care 21:153–158.  https://doi.org/10.1080/02813430310001806 CrossRefPubMedGoogle Scholar
  16. 16.
    Johnell K, Klarin I (2007) The relationship between number of drugs and potential drug-drug interactions in the elderly: a study of over 600,000 elderly patients from the Swedish Prescribed Drug Register. Drug Saf 30:911–918.  https://doi.org/10.2165/00002018-200730100-00009 CrossRefPubMedGoogle Scholar
  17. 17.
    Iyer S, Naganathan V, McLachlan AJ, Le Couteur DG (2008) Medication withdrawal trials in people aged 65 years and older: a systematic review. Drugs Aging 25:1021–1031.  https://doi.org/10.2165/0002512-200825120-00004 CrossRefPubMedGoogle Scholar
  18. 18.
    Urzal J, Pedro AB, Oliveira IF et al (2019) Inappropriate prescribing to elderly patients in an internal medicine ward. Acta Med Port 32:141–148.  https://doi.org/10.20344/amp.10683 CrossRefPubMedGoogle Scholar
  19. 19.
    Forgacs I, Loganayagam A (2008) Overprescribing proton pump inhibitors. BMJ 336:2–3.  https://doi.org/10.1136/bmj.39406.449456.BE CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Royal Academy of Medicine in Ireland 2019

Authors and Affiliations

  1. 1.ASL Città di TorinoTurinItaly
  2. 2.Department of Medical Sciences, Division of GastroenterologyUniversity of TurinTurinItaly
  3. 3.Unit of GastroenterologyMolinette HospitalTurinItaly
  4. 4.Department of Surgical SciencesUniversity of TurinTurinItaly

Personalised recommendations